Titre : Lions

Lions : Questions médicales fréquentes

Termes MeSH sélectionnés :

Poly(ADP-ribose) Polymerase Inhibitors
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Lions : Questions médicales les plus fréquentes", "headline": "Lions : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Lions : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-04", "dateModified": "2025-03-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Lions" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Panthera", "url": "https://questionsmedicales.fr/mesh/D046009", "about": { "@type": "MedicalCondition", "name": "Panthera", "code": { "@type": "MedicalCode", "code": "D046009", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B01.050.150.900.649.313.750.377.750.600" } } }, "about": { "@type": "MedicalCondition", "name": "Lions", "alternateName": "Lions", "code": { "@type": "MedicalCode", "code": "D008045", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Martin Haulena", "url": "https://questionsmedicales.fr/author/Martin%20Haulena", "affiliation": { "@type": "Organization", "name": "Vancouver Aquarium, Vancouver, BC V6G 3E2, Canada." } }, { "@type": "Person", "name": "Mads F Bertelsen", "url": "https://questionsmedicales.fr/author/Mads%20F%20Bertelsen", "affiliation": { "@type": "Organization", "name": "Centre for Zoo and Wild Animal Health, Copenhagen Zoo, Frederiksberg, Denmark." } }, { "@type": "Person", "name": "Diego Páez-Rosas", "url": "https://questionsmedicales.fr/author/Diego%20P%C3%A1ez-Rosas", "affiliation": { "@type": "Organization", "name": "Galapagos Science Center, Universidad San Francisco de Quito, Isla San Cristóbal, Islas Galápagos EC200150, Ecuador." } }, { "@type": "Person", "name": "Vincent N Naude", "url": "https://questionsmedicales.fr/author/Vincent%20N%20Naude", "affiliation": { "@type": "Organization", "name": "School of Animal, Plant & Environmental Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa." } }, { "@type": "Person", "name": "Vivienne L Williams", "url": "https://questionsmedicales.fr/author/Vivienne%20L%20Williams", "affiliation": { "@type": "Organization", "name": "School of Animal, Plant & Environmental Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Real-world Outcomes Associated With Poly(ADP-ribose) Polymerase Inhibitor Monotherapy Maintenance in Patients With Primary Advanced Ovarian Cancer.", "datePublished": "2023-04-28", "url": "https://questionsmedicales.fr/article/37106485", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/COC.0000000000001010" } }, { "@type": "ScholarlyArticle", "name": "Inhibition of efflux transporters by poly ADP-ribose polymerase inhibitors.", "datePublished": "2023-08-24", "url": "https://questionsmedicales.fr/article/37539467", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/bcpt.13928" } }, { "@type": "ScholarlyArticle", "name": "A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.", "datePublished": "2023-01-31", "url": "https://questionsmedicales.fr/article/36718624", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cncr.34662" } }, { "@type": "ScholarlyArticle", "name": "Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion.", "datePublished": "2024-10-11", "url": "https://questionsmedicales.fr/article/39393037", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1200/PO.24.00254" } }, { "@type": "ScholarlyArticle", "name": "A functional polymorphism in the poly(ADP-ribose) polymerase-1 gene increases the risk of endometrial carcinoma.", "datePublished": "2022-08-25", "url": "https://questionsmedicales.fr/article/36006023", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/01443615.2022.2114325" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Eucaryotes", "item": "https://questionsmedicales.fr/mesh/D056890" }, { "@type": "ListItem", "position": 3, "name": "Animaux", "item": "https://questionsmedicales.fr/mesh/D000818" }, { "@type": "ListItem", "position": 4, "name": "Chordés", "item": "https://questionsmedicales.fr/mesh/D043344" }, { "@type": "ListItem", "position": 5, "name": "Vertébrés", "item": "https://questionsmedicales.fr/mesh/D014714" }, { "@type": "ListItem", "position": 6, "name": "Mammifères", "item": "https://questionsmedicales.fr/mesh/D008322" }, { "@type": "ListItem", "position": 7, "name": "Eutheria", "item": "https://questionsmedicales.fr/mesh/D000073566" }, { "@type": "ListItem", "position": 8, "name": "Carnivora", "item": "https://questionsmedicales.fr/mesh/D002335" }, { "@type": "ListItem", "position": 9, "name": "Feliformia", "item": "https://questionsmedicales.fr/mesh/D000073568" }, { "@type": "ListItem", "position": 10, "name": "Felidae", "item": "https://questionsmedicales.fr/mesh/D045989" }, { "@type": "ListItem", "position": 11, "name": "Panthera", "item": "https://questionsmedicales.fr/mesh/D046009" }, { "@type": "ListItem", "position": 12, "name": "Lions", "item": "https://questionsmedicales.fr/mesh/D008045" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Lions - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Lions", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Lions", "description": "Comment identifier un lion dans la nature ?\nQuels tests pour évaluer la santé d'un lion ?\nQuels signes indiquent une maladie chez un lion ?\nComment diagnostiquer une infection chez un lion ?\nQuels sont les indicateurs de stress chez un lion ?", "url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Poly(ADP-ribose)+Polymerase+Inhibitors&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Lions", "description": "Quels symptômes d'une maladie courante chez les lions ?\nComment reconnaître une douleur chez un lion ?\nQuels signes indiquent une infection parasitaire ?\nQuels symptômes d'une maladie respiratoire chez un lion ?\nComment un lion montre-t-il des signes de dépression ?", "url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Poly(ADP-ribose)+Polymerase+Inhibitors&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Lions", "description": "Comment prévenir les maladies chez les lions ?\nQuelles mesures pour éviter les blessures chez les lions ?\nComment éviter le stress chez les lions en captivité ?\nQuelles pratiques alimentaires pour la santé des lions ?\nComment protéger les lions dans leur habitat naturel ?", "url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Poly(ADP-ribose)+Polymerase+Inhibitors&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Lions", "description": "Quels traitements pour une infection chez un lion ?\nComment traiter une blessure chez un lion ?\nQuels médicaments sont utilisés pour les lions ?\nComment gérer le stress chez un lion ?\nQuels soins préventifs pour les lions en captivité ?", "url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Poly(ADP-ribose)+Polymerase+Inhibitors&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Lions", "description": "Quelles complications peuvent survenir après une chirurgie chez un lion ?\nQuels risques de maladies chroniques chez les lions ?\nComment les maladies infectieuses affectent-elles les lions ?\nQuelles complications liées à l'âge chez les lions ?\nQuels effets du stress chronique sur les lions ?", "url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Poly(ADP-ribose)+Polymerase+Inhibitors&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Lions", "description": "Quels facteurs augmentent le risque de maladies chez les lions ?\nComment le braconnage affecte-t-il les lions ?\nQuels impacts de la perte d'habitat sur les lions ?\nComment le changement climatique affecte-t-il les lions ?\nQuels risques liés à la captivité pour les lions ?", "url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Poly(ADP-ribose)+Polymerase+Inhibitors&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier un lion dans la nature ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un lion se distingue par sa crinière, son rugissement et son comportement social en groupe." } }, { "@type": "Question", "name": "Quels tests pour évaluer la santé d'un lion ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des examens cliniques, des analyses sanguines et des radiographies sont utilisés." } }, { "@type": "Question", "name": "Quels signes indiquent une maladie chez un lion ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Perte d'appétit, léthargie, changements de comportement ou de pelage peuvent indiquer une maladie." } }, { "@type": "Question", "name": "Comment diagnostiquer une infection chez un lion ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests microbiologiques et des analyses de sang sont nécessaires pour diagnostiquer une infection." } }, { "@type": "Question", "name": "Quels sont les indicateurs de stress chez un lion ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un lion stressé peut montrer des comportements agités, des vocalisations excessives ou de l'agressivité." } }, { "@type": "Question", "name": "Quels symptômes d'une maladie courante chez les lions ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent la toux, des vomissements, et des changements d'appétit." } }, { "@type": "Question", "name": "Comment reconnaître une douleur chez un lion ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Un lion peut montrer des signes de douleur par des vocalisations, une posture anormale ou une agressivité." } }, { "@type": "Question", "name": "Quels signes indiquent une infection parasitaire ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Perte de poids, diarrhée et pelage terne peuvent indiquer une infection parasitaire." } }, { "@type": "Question", "name": "Quels symptômes d'une maladie respiratoire chez un lion ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Toux, respiration rapide et écoulement nasal sont des symptômes de maladie respiratoire." } }, { "@type": "Question", "name": "Comment un lion montre-t-il des signes de dépression ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Un lion déprimé peut devenir apathique, éviter les interactions sociales et perdre de l'appétit." } }, { "@type": "Question", "name": "Comment prévenir les maladies chez les lions ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des vaccinations régulières et une bonne hygiène sont essentielles pour prévenir les maladies." } }, { "@type": "Question", "name": "Quelles mesures pour éviter les blessures chez les lions ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un habitat sécurisé et des interactions contrôlées peuvent réduire le risque de blessures." } }, { "@type": "Question", "name": "Comment éviter le stress chez les lions en captivité ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Offrir un espace suffisant et des activités stimulantes aide à prévenir le stress." } }, { "@type": "Question", "name": "Quelles pratiques alimentaires pour la santé des lions ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et adaptée à leur espèce est cruciale pour leur santé." } }, { "@type": "Question", "name": "Comment protéger les lions dans leur habitat naturel ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "La conservation des habitats et la lutte contre le braconnage sont essentielles." } }, { "@type": "Question", "name": "Quels traitements pour une infection chez un lion ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les infections peuvent être traitées avec des antibiotiques et des soins de soutien." } }, { "@type": "Question", "name": "Comment traiter une blessure chez un lion ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les blessures nécessitent un nettoyage, des sutures et parfois des antibiotiques pour prévenir l'infection." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour les lions ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des analgésiques, des anti-inflammatoires et des antibiotiques sont couramment utilisés." } }, { "@type": "Question", "name": "Comment gérer le stress chez un lion ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des environnements enrichis et des interactions sociales peuvent aider à réduire le stress." } }, { "@type": "Question", "name": "Quels soins préventifs pour les lions en captivité ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des vaccinations, des examens réguliers et une alimentation équilibrée sont essentiels." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après une chirurgie chez un lion ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'infection, les saignements et les réactions anesthésiques." } }, { "@type": "Question", "name": "Quels risques de maladies chroniques chez les lions ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les lions peuvent développer des maladies chroniques comme l'arthrite ou des maladies cardiaques." } }, { "@type": "Question", "name": "Comment les maladies infectieuses affectent-elles les lions ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les maladies infectieuses peuvent entraîner des épidémies et affecter la population de lions." } }, { "@type": "Question", "name": "Quelles complications liées à l'âge chez les lions ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les lions âgés peuvent souffrir de problèmes articulaires, de perte de dents et de maladies organiques." } }, { "@type": "Question", "name": "Quels effets du stress chronique sur les lions ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut entraîner des problèmes de santé mentale et physique chez les lions." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de maladies chez les lions ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge avancé, le stress et une mauvaise nutrition augmentent le risque de maladies." } }, { "@type": "Question", "name": "Comment le braconnage affecte-t-il les lions ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Le braconnage réduit les populations de lions et augmente le risque d'extinction." } }, { "@type": "Question", "name": "Quels impacts de la perte d'habitat sur les lions ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "La perte d'habitat entraîne une diminution des ressources alimentaires et des conflits avec les humains." } }, { "@type": "Question", "name": "Comment le changement climatique affecte-t-il les lions ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Le changement climatique modifie les écosystèmes, affectant la disponibilité de proies et d'eau." } }, { "@type": "Question", "name": "Quels risques liés à la captivité pour les lions ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les lions en captivité peuvent souffrir de stress, de maladies et de comportements anormaux." } } ] } ] }

Sources (10000 au total)

Real-world Outcomes Associated With Poly(ADP-ribose) Polymerase Inhibitor Monotherapy Maintenance in Patients With Primary Advanced Ovarian Cancer.

This study used real-world population data to assess the trends of first-line (1L) poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance treatment uptake and outcomes in patients with primary adva... Patients diagnosed with AOC between January 1, 2017, and June 30, 2021, who completed 1L chemotherapy were selected from a real-world database. Descriptive analyses were performed to evaluate patient ... Of 705 patients who completed 1L chemotherapy, 166 received PARPi monotherapy and 539 underwent active surveillance (AS). Median follow-up was 10.9 months for PARPi monotherapy and 20.6 months for AS.... Our real-world analysis suggested that 47% of patients with primary AOC did not receive PARPi maintenance in the year 2021. PARPi use was associated with significantly improved outcomes compared with ...

A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.

Senaparib is a novel, selective poly(ADP-ribose) polymerase-1/2 inhibitor with strong antitumor activity in preclinical studies. This first-in-human, phase 1, dose-escalation study examined the safety... Patients with advanced solid tumors were enrolled from three centers in Australia, using a conventional 3 + 3 design. Dose-escalation cohorts continued until the maximum tolerated dose or a recommende... Thirty-nine patients were enrolled at 10 dose levels ranging from 2 to 150 mg. No dose-limiting toxicities were observed in any cohort. Most treatment-emergent adverse events were grade 1-2 (91%). Sev... Senaparib was well tolerated in Australian patients with advanced solid tumors, with encouraging signals of antitumor activity. The recommended phase 2 dose for senaparib was determined to be 100 mg d... NCT03507543....

Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.

Histone deacetylase inhibitors (HDACi) can modulate the acetylation status of proteins, influencing the genomic instability exhibited by cancer cells. Poly (ADP ribose) polymerase (PARP) inhibitors (P...

Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunities.

Poly (ADP-ribose) polymerase-1 (PARP-1) is the most extensively studied member of the PARP superfamily, with its primary function being the facilitation of DNA damage repair processes. Parthanatos is ...

Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database.

Poly(ADP-ribose) polymerase inhibitors (PARPi) are increasingly used in oncology; their hematological toxicities affect classically red, platelet and neutrophil lineages, but some opportunistic infect... This study was designed to provide an external and internal analysis of the crossed impacts of PARPi and age on lymphopenia risk.... A scoping review was performed on the PubMed and Embase databases to assess the reporting of lymphocyte rates in original studies on PARPi treatment for adult patients up to 1 April 2022. A retrospect... The scoping review research strategy retrieved 5840 abstracts; 225 studies were selected for full-text analysis. Lymphopenia was reported in 41.8% of the studies; frequency of all-grade and grade ≥ 3 ... Lymphopenia events were much more frequent in real-life than in previously reported studies, particularly in older patients. Future work is needed to improve patient follow-up and discuss prophylactic...

The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.

Ovarian cancer (OC) is associated with the highest gynecologic cancer mortality. The development of novel, effective combinations of targeted therapeutics remains an unmet medical need. We evaluated t... In vitro cell viability with olaparib, neratinib, and their combination was assessed using flow-cytometry based assays against a panel of OC primary cell lines with variable HER2 expression. Immunoblo... HER2 + OC cell lines demonstrated higher sensitivity to olaparib and neratinib when compared to HER2 negative tumors (i.e., IC... The combination of olaparib and neratinib is synergistic and endowed with remarkable preclinical activity against HER2+ ovarian cancers. This combination may represent a novel therapeutic option for o...

Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.

Poly(ADP-ribose) polymerase 1 (PARP1) regulates a myriad of DNA repair mechanisms to preserve genomic integrity following DNA damage. PARP inhibitors (PARPi) confer synthetic lethality in malignancies...